Cite
Mosunetuzumab with polatuzumab vedotin in relapsed or refractory aggressive large B cell lymphoma: a phase 1b/2 trial.
MLA
Budde, Lihua E., et al. “Mosunetuzumab with Polatuzumab Vedotin in Relapsed or Refractory Aggressive Large B Cell Lymphoma: A Phase 1b/2 Trial.” Nature Medicine, vol. 30, no. 1, Jan. 2024, pp. 229–39. EBSCOhost, https://doi.org/10.1038/s41591-023-02726-5.
APA
Budde, L. E., Olszewski, A. J., Assouline, S., Lossos, I. S., Diefenbach, C., Kamdar, M., Ghosh, N., Modi, D., Sabry, W., Naik, S., Mehta, A., Nakhoda, S. K., Smith, S. D., Dorritie, K., Jia, T., Pham, S., Huw, L.-Y., Jing, J., Wu, H., … Chavez, J. C. (2024). Mosunetuzumab with polatuzumab vedotin in relapsed or refractory aggressive large B cell lymphoma: a phase 1b/2 trial. Nature Medicine, 30(1), 229–239. https://doi.org/10.1038/s41591-023-02726-5
Chicago
Budde, Lihua E, Adam J Olszewski, Sarit Assouline, Izidore S Lossos, Catherine Diefenbach, Manali Kamdar, Nilanjan Ghosh, et al. 2024. “Mosunetuzumab with Polatuzumab Vedotin in Relapsed or Refractory Aggressive Large B Cell Lymphoma: A Phase 1b/2 Trial.” Nature Medicine 30 (1): 229–39. doi:10.1038/s41591-023-02726-5.